Initiation, Switching, and Cessation of Psoriasis Treatments Among Patients with Moderate to Severe Psoriasis in the United States-Reference-Cited by-同舟云学术

Initiation, Switching, and Cessation of Psoriasis Treatments Among Patients with Moderate to Severe Psoriasis in the United States

Published:2017-03-16 Issue:5 Volume:37 Page:493-501
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Armstrong April W.,Koning J. Will,Rowse Simon,Tan Huaming,Mamolo Carla,Kaur Mandeep

Funder

Pfizer

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s40261-017-0508-1.pdf

Reference31 articles.

1. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70:512–6.

2. Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015;151:651–8.

3. Vanderpuye-Orgle J, Zhao Y, Lu J, Shrestha A, Sexton A, Seabury S, et al. Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol. 2015;72:961–7.

4. Lewis-Beck C, Abouzaid S, Xie L, Baser O, Kim E. Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling. Patient Prefer Adherence. 2013;7:199–205.

5. American Academy of Dermatology. Position statement on treatment of psoriatic patients. 2013. Available at: https://www.aad.org/Forms/Policies/Uploads/PS/PS%20on%20Treatment%20of%20Psoriatic%20Patients.pdf . Accessed 9 Dec 2016.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dysregulation of epigenetic, biological and mitotic age in the context of biologic drug treatment and phototherapy in plaque psoriasis patients;Journal of the European Academy of Dermatology and Venereology;2024-04-15

2. Use of systemic and biological therapy in patients with moderate-to-severe psoriasis;Clinical and Experimental Dermatology;2023-08-23

3. Trajectories of systemic agent use and associated depression- and anxiety-related health care costs among patients with psoriasis;JAAD International;2022-12

4. Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review;Rheumatology;2022-03-14

5. Treatment utilization and drug survival of systemic medications among commercially insured children with psoriasis;Pediatric Dermatology;2021-08-31